STUDIES IN GLAUCOMATOUS OPTIC NERVE DAMAGE
STUDIES IN GLAUCOMATOUS OPTIC NERVE DAMAGE
批准号:
6819742
负责人:
JOHN C MORRISON
金额:
$37.75万
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-04-01 至 2006-02-28
关键词:
agingapoptosisaxonbrain derived neurotrophic factorcellular pathologyenzyme linked immunosorbent assayglaucomaglaucoma testgrowth factor receptorsimmunocytochemistryin situ hybridizationintraocular pressurelaboratory ratmessenger RNAmicroinjectionsnerve injuryneural degenerationneuronal transportnucleic acid probesoptic nervepolymerase chain reactionposttranslational modificationsprotein tyrosine kinasereceptor expressionretinal ganglionwestern blottings
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Retinal ganglion cell (RGC) survival is
thought to depend on the level of activation of TrkB receptors by the
endogenous neurotrophins, BDNF and NT4/5. These neurotrophins (NT) are derived
from the superior colliculus, and complex with specific TrkB receptors. They
then travel by retrograde axonal transport to the RCG cell body. There they act
to preserve RGC by stimulating specific cell survival pathways, and by
inhibiting specific cell death pathways (apoptosis).
Elevated intraocular pressure (IOP), a major risk factor for glaucoma,
obstructs axonal transport, and has been shown to inhibit delivery of NT to the
RGC. In addition, there is good reason to believe that other risk factors for
glaucoma, such as aging and previous optic nerve damage, may also affect this
system, possibly by reducing the production of TrkB receptors, the production
of NT, or both. These facts lead to the hypothesis that, in glaucoma, RGC death
results from a reduction in the activation of neurotrophin-dependent TrkB
mediated survival pathways.
Using Brown Norway rats, methods now exist for modeling chronically elevated
IOP, surgically lowering IOP, and studying these phenomena in aged, as well as
young adult animals. This proposal will determine the effects of these three
important glaucoma risk factors on neurotrophin TrkB activated survival
signaling pathways and on RGC survival. A final specific aim will
pharmacologically enhance the activity of NT-mediated cell survival pathways in
partially damaged eyes following IOP control. This models the most common
clinical situation in glaucoma. Success will be gauged by measuring decreased
RGC loss, as well as changes in NT-mediated signaling pathways that enhance
survival. These experiments will help to determine the potential for agents
that enhance TrkB-activation in RGCs as a neuroprotective therapy for glaucoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mentored Vision Clinician-Scientist Program at OHSU
-
批准号:9913547
-
项目类别:
-
资助金额:$26.57万
-
财政年份:2018
-
负责人:JOHN C MORRISON
-
依托单位:
Mentored Vision Clinician-Scientist Program at OHSU
-
批准号:10397548
-
项目类别:
-
资助金额:$26.57万
-
财政年份:2018
-
负责人:JOHN C MORRISON
-
依托单位:
Ophthalmology Core Facility
-
批准号:10707492
-
项目类别:
-
资助金额:$76.75万
-
财政年份:1997
-
负责人:JOHN C MORRISON
-
依托单位:
Ophthalmology Core Facility
-
批准号:9129695
-
项目类别:
-
资助金额:$77.0万
-
财政年份:1997
-
负责人:JOHN C MORRISON
-
依托单位:
Ophthalmology Core Facility
-
批准号:9552816
-
项目类别:
-
资助金额:$76.4万
-
财政年份:1997
-
负责人:JOHN C MORRISON
-
依托单位:
Administrative Core
-
批准号:10707525
-
项目类别:
-
资助金额:$3.03万
-
财政年份:1997
-
负责人:JOHN C MORRISON
-
依托单位:
Ophthalmology Core Facility
-
批准号:8937422
-
项目类别:
-
资助金额:$75.93万
-
财政年份:1997
-
负责人:JOHN C MORRISON
-
依托单位:
Ophthalmology Core Facility
-
批准号:9762946
-
项目类别:
-
资助金额:$76.75万
-
财政年份:1997
-
负责人:JOHN C MORRISON
-
依托单位:
Administrative Core
-
批准号:10250833
-
项目类别:
-
资助金额:$3.4万
-
财政年份:1997
-
负责人:JOHN C MORRISON
-
依托单位:
Ophthalmology Core Facility
-
批准号:10250444
-
项目类别:
-
资助金额:$76.75万
-
财政年份:1997
-
负责人:JOHN C MORRISON
-
依托单位:
Ophthalmology Core Facility
-
批准号:10020817
-
项目类别:
-
资助金额:$76.75万
-
财政年份:1997
-
负责人:JOHN C MORRISON
-
依托单位:
GLAUCOMATOUS OPTIC NERVE DAMAGE
-
批准号:2163856
-
项目类别:
-
资助金额:$17.17万
-
财政年份:1993
-
负责人:JOHN C MORRISON
-
依托单位:
Studies in Glaucomatous Optic Nerve Damage
-
批准号:7584008
-
项目类别:
-
资助金额:$38.28万
-
财政年份:1993
-
负责人:JOHN C MORRISON
-
依托单位:
GLAUCOMATOUS OPTIC NERVE DAMAGE
-
批准号:3267369
-
项目类别:
-
资助金额:$11.71万
-
财政年份:1993
-
负责人:JOHN C MORRISON
-
依托单位:
Studies in Glaucomatous Optic Nerve Damage
-
批准号:8623130
-
项目类别:
-
资助金额:$61.2万
-
财政年份:1993
-
负责人:JOHN C MORRISON
-
依托单位:
GLAUCOMATOUS OPTIC NERVE DAMAGE
-
批准号:2838343
-
项目类别:
-
资助金额:$29.09万
-
财政年份:1993
-
负责人:JOHN C MORRISON
-
依托单位:
GLAUCOMATOUS OPTIC NERVE DAMAGE
-
批准号:6125112
-
项目类别:
-
资助金额:$20.87万
-
财政年份:1993
-
负责人:JOHN C MORRISON
-
依托单位:
Studies in Glaucomatous Optic Nerve Damage
-
批准号:8504209
-
项目类别:
-
资助金额:$64.88万
-
财政年份:1993
-
负责人:JOHN C MORRISON
-
依托单位:
Studies in Glaucomatous Optic Nerve Damage
-
批准号:10221683
-
项目类别:
-
资助金额:$47.91万
-
财政年份:1993
-
负责人:JOHN C MORRISON
-
依托单位:
Studies in Glaucomatous Optic Nerve Damage
-
批准号:10436849
-
项目类别:
-
资助金额:$47.91万
-
财政年份:1993
-
负责人:JOHN C MORRISON
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
去乙酰化酶SIRT1在前体mRNA可变剪切中的作用及其生理病理效应研究
-
批准号:31970691
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:张胜萍
-
依托单位:
TM9SF4调控非小细胞肺癌细胞凋亡机制研究
-
批准号:31900527
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:孙磊
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
姜黄素与TRAIL的协同抗肿瘤机制研究
-
批准号:31101223
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2011
-
负责人:曹林
-
依托单位:
转凝蛋白通过线粒体凋亡途径致足细胞凋亡的机制研究
-
批准号:81100502
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:管娜
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位: